BMS-986158, a Potent BET Inhibitor, in Combination with Ruxolitinib or Fedratinib in Patients (pts) with Intermediate- or High-Risk Myelofibrosis (MF): Updated Results from a Phase 1/2 Study
Lavie, David, Ribrag, Vincent, Loschi, Michael, Yannakou, Costas K., Alwan, Maan, Abulafia, Adi Schacham, Hernández-Rivas, Jesús María, Volchek, Yulia, Fong, Chun Yew, Bonifacio, Massimiliano, Kiladjian, Jean-Jacques, Ianotto, Jean-Christophe, García Gutiérrez, Valentín, Tucci, Alessandra, Xicoy, Blanca, Al-Ali, Haifa Kathrin, Talpaz, Moshe, Gerber, Jonathan M., Raman, Indu, Tomuleasa, Ciprian, Lee-Hoeflich, Si Tuen, Das, Sharmila, Wu, Bin, Zhao, Qian, Kim, Eunhee, Esposito, Oriana, Liu, Yu, Nikolova, Zariana, Tehlirian, Christopher, Coker, Shodeinde, Ayala, Rosa
Published in Blood (02.11.2023)
Published in Blood (02.11.2023)
Get full text
Journal Article